



Proventys Appoints Surya Singh, M.D., as Chief Medical Officer and Vice President of Clinical Development

Dr. Singh Brings Extensive Expertise in Predictive Medicine and Developing Innovative Healthcare Solutions

NEWTON, MA, April 1, 2009 – Proventys, a healthcare technology company developing next-generation decision support solutions delivered at the point of care, today announced the appointment of Surya Singh, M.D. as chief medical officer and vice president of clinical development. In his new role, Dr. Singh will be responsible for driving the company's development and validation of novel, software-based solutions that help clinicians predict patient outcomes and personalize care.

Dr. Singh brings a wealth of clinical and operational experience to Proventys, having served most recently as chief medical officer and senior vice president of client solutions and clinical operations at D2Hawkeye, a market-leading, healthcare data mining and predictive modeling company. In this role, Dr. Singh led all aspects of clinical product development, directed the company's Medical Advisory Group and handled all business development activity targeting Medicare and Medicaid.

"We are thrilled to welcome Dr. Singh to the senior management team at this significant stage in our company's development," said Proventys CEO Tim Thompson. "The breadth and depth of Dr. Singh's experience in clinical operations and healthcare strategy makes him the ideal leader in the enhancement and expansion of our predictive technologies suite. As we approach the introduction of our personalized, point-of-care solutions, Dr. Singh's background complements the strong technology and commercialization expertise of our current senior leadership team."

"Proventys' unique dedication to delivering innovative solutions to physicians facing complex clinical decisions aligns nicely with my recent focus on predictive medicine," said Dr. Singh. "I look forward to playing a meaningful role in the advancement of Proventys' vision by collaborating with key scientific and medical leaders in the industry and building upon the company's strong foundation."

Prior to joining D2Hawkeye, Dr. Singh served as engagement manager at McKinsey and Company, where he helped construct comprehensive product quality and growth strategies for commercial and academic healthcare organizations, and developed and modeled electronic health record (EHR) adoption strategies by partnering with a variety of constituencies.

Dr. Singh holds a bachelor's degree in molecular biology from the University of Texas and a medical doctorate from Johns Hopkins University. He completed his Harvard-based internal medicine residency at Brigham and Women's Hospital in Boston, and

continues to serve as an attending physician and instructor in medicine at Brigham and Women's Hospital and Harvard Medical School.

About Proventys

Based in Durham, NC and Newton, MA, Proventys is a healthcare technology company developing next-generation decision support solutions that help clinicians predict patient outcomes and personalize care. At the core of its product portfolio, the company is developing software-based, predictive diagnostics (PDx) that quantify and assess a patient's individualized risk of specific adverse events, potential disease progression, or likely response to a given therapy. The products will be delivered at the point of care through the Proventys PDx System™, which operates as a standalone web-based application, and as an integrated utility within electronic medical record and other systems. Proventys has relationships with leading researchers in oncology, cardiology and other areas, and a strategic partnership with McKesson Corporation. By helping clinicians predict patient outcomes and supporting important clinical decisions, Proventys is enabling a more prospective, personalized approach to healthcare. For more information, visit www.proventys.com.

###

Media Contact:

Jackie Hanley
Racepoint Group
781-487-4625
jhanley@racepointgroup.com